查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606914

癌症诊断人工智慧的全球市场（按组成部分、按癌症类型、按最终用户、按地区（北美、欧洲、亚太地区、拉丁美洲、中东和非洲））：趋势分析、竞争格局、未来预测（2019年） -2030)

AI in Cancer Diagnostics Market, By Component; By Cancer Type; By End User; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa ), Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 521 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球癌症诊断人工智慧市场将扩大八倍，到 2030 年达到 50 亿美元。

由于技术进步、癌症发病率上升以及对早期检测和个人化医疗的需求不断增长，全球癌症诊断人工智慧市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2023 年全球癌症诊断人工智慧市场以金额为准将达到 6.433 亿美元。 BlueWeave 预测，在 2024 年至 2030 年的预测期内，全球癌症诊断人工智慧市场规模将以 34.60% 的复合年增长率强劲增长，到 2030 年达到 50.949 亿美元。机器学习演算法和成像技术的进步推动了用于癌症诊断的人工智慧的全球市场，这些技术可以实现更快、更准确的癌症检测。全球癌症盛行率不断上升，加上对个人化治疗的需求不断增长，正在推动人工智慧的采用。将人工智慧与 MRI 和电脑断层扫描等影像方式结合将提高诊断准确性。政府对医疗保健领域人工智慧的支持和资助，以及科技公司和医疗机构之间的伙伴关係将进一步推动市场成长。成本效率和诊断错误的减少将推动全球癌症诊断人工智慧市场的快速成长。

机会 - 日益关注诊断和成本效率

采用人工智慧进行癌症诊断可以提高诊断准确性，加快医疗资料分析速度，并更快获得结果。人工智慧驱动的工具可以比传统方法更快地处理大量资料和遗传资料，从而减少手动解释的需要。这种效率不仅可以改善患者的治疗效果，还可以降低医疗保健提供者的营运成本，使先进的诊断更容易获得和负担得起，并推动癌症诊断市场的成长。

地缘政治紧张局势加剧对全球癌症诊断人工智慧市场的影响

不断升级的地缘政治紧张局势可能会阻碍跨境合作、减缓技术进步并限制对重要资料和研究的获取，从而扰乱全球癌症诊断人工智慧市场。贸易限制可能会减缓人工智慧主导的诊断工具的开发，紧张的国际关係可能会影响投资和资金筹措。此外，不同地区的监管挑战可能会使市场成长更加复杂，减少癌症诊断人工智慧解决方案的采用，并影响全球医疗保健的普及。

软体解决方案领域引领全球癌症诊断人工智慧市场

软体解决方案领域是全球癌症诊断人工智慧市场的关键组成部分。越来越多地使用人工智慧主导的诊断工具来提高诊断准确性和效率，例如影像分析、生物标记检测和风险评估，正在推动人工智慧引领市场。将先进演算法融入医疗平台，加上对软体进步的投资增加，在提高市场占有率方面发挥关键作用。此外，我们针对多种癌症类型的软体解决方案的扩充性和成本效益进一步巩固了我们的市场优势。

竞争格局

全球癌症诊断人工智慧市场竞争激烈，许多企业争夺更大的市场占有率。市场主要企业包括Ibex Medical Analytics、Paige AI、PathAI、Tempus、Freenome、Enlitic、CureMetrix、Owkin、DeepBio、AIRA Matrix、Indica Labs、Mindpeak等。这些公司正在利用各种策略，包括增加研发活动併购、合资、联盟、许可协议以及发布新产品和服务，以进一步主导全球癌症诊断人工智慧市场。

该报告的详细分析提供了全球癌症诊断人工智慧市场的成长潜力、未来趋势和统计资讯。它还重点关注推动市场总规模预测的因素。该报告致力于提供全球癌症诊断人工智慧市场的最新技术趋势和产业见解，帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 分析框架

第 2 章执行摘要

第三章市场考察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 提高诊断准确性
      • 早期发现与预防
      • 个人化医疗
    • 抑制因素
      • 资料品质和数量
      • 道德考虑和偏见
    • 机会
      • 提高效率并降低成本
      • 增加投资和监管支持
    • 任务
      • 实施成本高
      • 缺乏临床检验和招募
  • 科技进步/最新趋势
  • 法规结构
  • 波特五力分析

第四章 全球癌症诊断人工智慧市场：行销策略

第五章 全球癌症诊断人工智慧市场：区域分析

  • 全球癌症诊断人工智慧市场：区域分析（2023）
  • 全球癌症诊断人工智慧市场：市场魅力分析（2024-2030）

第六章全球癌症诊断人工智慧市场：概述

  • 市场规模及预测（2019-2030）
    • 以金额为准
  • 市场占有率及预测
    • 按成分
      • 软体解决方案
      • 硬体
      • 服务
    • 按癌症类型
      • 乳癌
      • 肺癌
      • 摄护腺癌
      • 大肠直肠癌
      • 脑肿瘤
      • 其他的
    • 按最终用户
      • 医院
      • 手术中心/医疗机构
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第七章 北美癌症诊断人工智慧市场

  • 市场规模及预测（2019-2030）
    • 以金额为准
  • 市场占有率及预测
    • 按成分
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第八章欧洲癌症诊断人工智慧市场

  • 市场规模及预测（2019-2030）
    • 以金额为准
  • 市场占有率及预测
    • 按成分
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第九章 亚太地区癌症诊断人工智慧市场

  • 市场规模及预测（2019-2030）
    • 以金额为准
  • 市场占有率及预测
    • 按成分
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲/纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

第十章拉丁美洲癌症诊断人工智慧市场

  • 市场规模及预测（2019-2030）
    • 以金额为准
  • 市场占有率及预测
    • 按成分
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第11章：中东和非洲癌症诊断的人工智慧市场

  • 市场规模及预测（2019-2030）
    • 以金额为准
  • 市场占有率及预测
    • 按成分
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第十二章竞争格局

  • 主要企业及其产品列表
  • 全球癌症诊断人工智慧公司：市场占有率分析（2023）
  • 竞争基准：按管理参数
  • 主要策略（企业合併、业务联盟）发展现状

第十三章 全球癌症诊断人工智慧市场：进口/出口

第十四章 地缘政治紧张局势加剧对全球癌症诊断人工智慧市场的影响

第十五章 公司简介（公司概况、财务矩阵、竞争格局、公司负责人、主要竞争对手、联络方式、策略展望）

  • Ibex Medical Analytics
  • Paige AI
  • PathAI
  • Tempus
  • Freenome
  • Enlitic
  • CureMetrix
  • Owkin
  • DeepBio
  • AIRA Matrix
  • Indica Labs
  • Mindpeak
  • 其他主要企业

第十六章 主要策略建议

第17章分析技术

简介目录
Product Code: BWC24905

Global AI in Cancer Diagnostics Market Size Zooms 8X to Surpass USD 5 Billion by 2030

Global AI in Cancer Diagnostics Market is thriving due to technological advancements, rising cancer prevalence, and a spurring demand for early detection and personalized medicine.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global AI in Cancer Diagnostics Market size by value at USD 643.3 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global AI in Cancer Diagnostics Market size to expand at a robust CAGR of 34.60% reaching a value of USD 5,094.9 million by 2030. Global AI in Cancer Diagnostics Market is driven by advancements in machine learning algorithms and imaging technologies, enabling faster and more accurate cancer detection. Increasing cancer prevalence across the world, coupled with rising demand for personalized treatment, fuels AI adoption. Integration of AI with imaging modalities like MRI and CT scans enhances diagnostic precision. Supportive government initiatives and funding for AI in healthcare, along with partnerships between tech firms and medical institutions, further propel market growth. Cost efficiency and reduced diagnostic errors add momentum to the rapid growth of Global AI in Cancer Diagnostics Market.

Opportunity -Increasing Focus on Diagnostic and Cost Efficiency

The adoption of AI in cancer diagnostics enhances diagnostic accuracy and speeds up the analysis of medical data, leading to quicker results. AI-powered tools can process vast amounts of imaging and genetic data faster than traditional methods, reducing the need for manual interpretation. This efficiency improves patient outcomes and also lowers operational costs for healthcare providers, making advanced diagnostics more accessible and affordable, which is driving market growth in cancer diagnostics.

Impact of Escalating Geopolitical Tensions on Global AI in Cancer Diagnostics Market

Escalating geopolitical tensions could disrupt Global AI in Cancer Diagnostics Market by hindering cross-border collaborations, slowing technological advancements, and limiting access to essential data and research. Trade restrictions may delay the development of AI-driven diagnostic tools, while strained international relations can impact investments and funding. Additionally, regulatory challenges across different regions could further complicate market growth, potentially reducing the adoption of AI solutions in cancer diagnostics and affecting healthcare accessibility globally.

Software Solutions Segment Leads Global AI in Cancer Diagnostics Market

The software solutions segment stands out as the leading component of Global AI in Cancer Diagnostics Market. The market leadership position of AI is fueled by the rising use of AI-driven diagnostic tools for tasks, such as image analysis, biomarker detection, and risk evaluation, which improve both diagnostic precision and efficiency. The incorporation of sophisticated algorithms into healthcare platforms, coupled with increased investments in software advancements, plays a crucial role in boosting its market share. Additionally, the scalability and cost-effectiveness of software solutions across various cancer types further solidify their dominant position in the market.

Competitive Landscape

Global AI in Cancer Diagnostics Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Ibex Medical Analytics, Paige AI, PathAI, Tempus, Freenome, Enlitic, CureMetrix, Owkin, DeepBio, AIRA Matrix, Indica Labs, and Mindpeak. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global AI in Cancer Diagnostics Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global AI in Cancer Diagnostics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global AI in Cancer Diagnostics Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global AI in Cancer Diagnostics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Enhanced Diagnostic Accuracy
      • 3.2.1.2. Early Detection and Prevention
      • 3.2.1.3. Personalized Medicine
    • 3.2.2. Restraints
      • 3.2.2.1. Data Quality and Quantity
      • 3.2.2.2. Ethical Considerations and Bias
    • 3.2.3. Opportunities
      • 3.2.3.1. Increased Efficiency and Reduced Costs
      • 3.2.3.2. Growing Investment and Regulatory Support
    • 3.2.4. Challenges
      • 3.2.4.1. High Cost of Implementation
      • 3.2.4.2. Lack of Clinical Validation and Adoption
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global AI in Cancer Diagnostics Market: Marketing Strategies

5. Global AI in Cancer Diagnostics Market: Geographical Analysis

  • 5.1. Global AI in Cancer Diagnostics Market, Geographical Analysis, 2023
  • 5.2. Global AI in Cancer Diagnostics Market, Market Attractiveness Analysis, 2024-2030

6. Global AI in Cancer Diagnostics Market Overview

  • 6.1. Market Size & Forecast, 2019-2030
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
      • 6.2.1.1. Software Solutions
      • 6.2.1.2. Hardware
      • 6.2.1.3. Services
    • 6.2.2. By Cancer Type
      • 6.2.2.1. Breast Cancer
      • 6.2.2.2. Lung Cancer
      • 6.2.2.3. Prostate Cancer
      • 6.2.2.4. Colorectal Cancer
      • 6.2.2.5. Brain Tumor
      • 6.2.2.6. Others
    • 6.2.3. By End User
      • 6.2.3.1. Hospitals
      • 6.2.3.2. Surgical Centers & Medical Institutes
      • 6.2.3.3. Others
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America AI in Cancer Diagnostics Market

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Cancer Type
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Component
      • 7.2.4.1.2. By Cancer Type
      • 7.2.4.1.3. By End User
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Component
      • 7.2.4.2.2. By Cancer Type
      • 7.2.4.2.3. By End User

8. Europe AI in Cancer Diagnostics Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Cancer Type
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Component
      • 8.2.4.1.2. By Cancer Type
      • 8.2.4.1.3. By End User
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Component
      • 8.2.4.2.2. By Cancer Type
      • 8.2.4.2.3. By End User
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Component
      • 8.2.4.3.2. By Cancer Type
      • 8.2.4.3.3. By End User
      • 8.2.4.4. France
      • 8.2.4.4.1. By Component
      • 8.2.4.4.2. By Cancer Type
      • 8.2.4.4.3. By End User
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Component
      • 8.2.4.5.2. By Cancer Type
      • 8.2.4.5.3. By End User
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Component
      • 8.2.4.6.2. By Cancer Type
      • 8.2.4.6.3. By End User
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Component
      • 8.2.4.7.2. By Cancer Type
      • 8.2.4.7.3. By End User
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Component
      • 8.2.4.8.2. By Cancer Type
      • 8.2.4.8.3. By End User
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Component
      • 8.2.4.9.2. By Cancer Type
      • 8.2.4.9.3. By End User

9. Asia Pacific AI in Cancer Diagnostics Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Cancer Type
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Component
      • 9.2.4.1.2. By Cancer Type
      • 9.2.4.1.3. By End User
      • 9.2.4.2. India
      • 9.2.4.2.1. By Component
      • 9.2.4.2.2. By Cancer Type
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Component
      • 9.2.4.3.2. By Cancer Type
      • 9.2.4.3.3. By End User
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Component
      • 9.2.4.4.2. By Cancer Type
      • 9.2.4.4.3. By End User
      • 9.2.4.5. Australia & New Zealand
      • 9.2.4.5.1. By Component
      • 9.2.4.5.2. By Cancer Type
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Component
      • 9.2.4.6.2. By Cancer Type
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Component
      • 9.2.4.7.2. By Cancer Type
      • 9.2.4.7.3. By End User
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Component
      • 9.2.4.8.2. By Cancer Type
      • 9.2.4.8.3. By End User
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Component
      • 9.2.4.9.2. By Cancer Type
      • 9.2.4.9.3. By End User
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Component
      • 9.2.4.10.2. By Cancer Type
      • 9.2.4.10.3. By End User

10. Latin America AI in Cancer Diagnostics Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Cancer Type
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Component
      • 10.2.4.1.2. By Cancer Type
      • 10.2.4.1.3. By End User
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Component
      • 10.2.4.2.2. By Cancer Type
      • 10.2.4.2.3. By End User
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Component
      • 10.2.4.3.2. By Cancer Type
      • 10.2.4.3.3. By End User
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Component
      • 10.2.4.4.2. By Cancer Type
      • 10.2.4.4.3. By End User
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Component
      • 10.2.4.5.2. By Cancer Type
      • 10.2.4.5.3. By End User

11. Middle East & Africa AI in Cancer Diagnostics Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Million)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Cancer Type
    • 11.2.3. By End User
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Component
      • 11.2.4.1.2. By Cancer Type
      • 11.2.4.1.3. By End User
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Component
      • 11.2.4.2.2. By Cancer Type
      • 11.2.4.2.3. By End User
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Component
      • 11.2.4.3.2. By Cancer Type
      • 11.2.4.3.3. By End User
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Component
      • 11.2.4.4.2. By Cancer Type
      • 11.2.4.4.3. By End User
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Component
      • 11.2.4.5.2. By Cancer Type
      • 11.2.4.5.3. By End User
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Component
      • 11.2.4.6.2. By Cancer Type
      • 11.2.4.6.3. By End User
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Component
      • 11.2.4.7.2. By Cancer Type
      • 11.2.4.7.3. By End User
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Component
      • 11.2.4.8.2. By Cancer Type
      • 11.2.4.8.3. By End User

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global AI in Cancer Diagnostics Company Market Share Analysis, 2023
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

13. Global AI in Cancer Diagnostics Market: Import & Export

14. Impact of Escalating Geopolitical Tensions on Global AI in Cancer Diagnostics Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Ibex Medical Analytics
  • 15.2. Paige AI
  • 15.3. PathAI
  • 15.4. Tempus
  • 15.5. Freenome
  • 15.6. Enlitic
  • 15.7. CureMetrix
  • 15.8. Owkin
  • 15.9. DeepBio
  • 15.10. AIRA Matrix
  • 15.11. Indica Labs
  • 15.12. Mindpeak
  • 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable